Preliminary Data from Real-World Study Demonstrate T-cell Testing Outperforms Antibody Testing in Identifying Past SARS-CoV-2 Infections
November 13, 2020 08:00 ET
|
Adaptive Biotechnologies
– Findings support upcoming launch of T-Detect™ COVID, first T-cell test for novel coronavirus– Data support mounting evidence that measuring T-cells is necessary to fully characterize immune...
Adaptive Biotechnologies Announces Collaboration with GSK to Measure Minimal Residual Disease with clonoSEQ® Assay Across its Hematology and Oncology Portfolio
November 10, 2020 16:13 ET
|
Adaptive Biotechnologies
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results
November 10, 2020 16:10 ET
|
Adaptive Biotechnologies
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 10, 2020
October 13, 2020 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies to Present at the Morgan Stanley 2020 Healthcare Conference
September 01, 2020 16:03 ET
|
Adaptive Biotechnologies
SEATTLE, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Reports Second Quarter 2020 Financial Results
August 10, 2020 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innovations Summit
August 10, 2020 08:05 ET
|
Adaptive Biotechnologies
SEATTLE, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia
August 06, 2020 09:24 ET
|
Adaptive Biotechnologies
First and only FDA-cleared assay for MRD in CLL, multiple myeloma and ALLCLL clearance includes testing in blood; Adaptive collaborating with LabCorp® and Phlebotek Solutions® to provide clonoSEQ...
Adaptive Biotechnologies Launches immunoSEQ T-MAP COVID, First Molecular T Cell Monitoring Tool for SARS-CoV-2
August 04, 2020 09:30 ET
|
Adaptive Biotechnologies
Tailored for vaccine developers to accurately and reproducibly measure and track COVID-19 specific T-cell response in clinical trials Powered by T-cell immune response data from over 1,000 COVID-19...
Adaptive Biotechnologies Launches National Clinical Trial to Develop Novel T-Cell Based Diagnostic for Lyme Disease
July 28, 2020 18:04 ET
|
Adaptive Biotechnologies
SEATTLE, July 28, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corp. (Nasdaq: ADPT) announced today the launch of ImmuneSense Lyme™, a research study to inform the development of an improved...